NMD Pharma reported topline Phase 2a results for ignaseclant in Charcot-Marie-Tooth disease (CMT) types 1 and 2. The randomized, double-blind, placebo-controlled Synapse-CMT study in 81 adults did not meet its pre-specified primary endpoint, the 6-minute walk test at 21 days. However, patients on twice-daily oral ignaseclant showed consistent improvements on multiple secondary measures, including the validated CMT Functional Outcome Measure, handgrip strength, fine hand function, and patient-reported outcomes, with effects maintained at a follow-up visit one week after dosing ended. Safety was favorable with no serious adverse events. The company plans to accelerate development in CMT and will present detailed data in the first half of 2026, alongside ongoing mid-stage programs in generalized myasthenia gravis and spinal muscular atrophy.
The missed primary endpoint sets up the central strategic question: can a coherent suite of functional and patient-reported secondary outcomes carry an orphan neuromuscular program forward if the traditional ambulatory metric does not move in a short timeframe? For CMT, a heterogeneous, progressive neuropathy with no approved therapies, the choice of endpoints is not academic. Regulators and payers will need to see measures that are both clinically meaningful and sensitive to change, and industry teams must decide whether to anchor future trials on upper-limb function, composite scales, or longer-duration ambulatory assessments that better reflect disease biology.
This matters now because muscle-targeted pharmacology could offer the first scalable, oral option for a population currently limited to supportive care. The signals in hand strength and dexterity directly map to daily function, potentially resonating with patients and clinicians more than marginal changes in a short 6-minute walk assessment. For payers, the durability of benefit beyond the dosing window invites cautious optimism but demands confirmation over months, not weeks, with clear links to quality of life, independence, and reduced healthcare utilization. Medical Affairs teams face an immediate mandate to align with neuromuscular KOLs on endpoint relevance, educate HCPs on mechanism and patient selection across CMT1 and CMT2, and plan real-world evidence strategies that can complement trial readouts.
The readout also fits a broader neuromuscular pivot toward mechanisms that augment muscle excitability and function, complementing gene-targeted or immunologic approaches. Prior late-stage efforts in CMT have struggled to deliver unambiguous efficacy, and the field lacks an established regulatory precedent for approval endpoints. If ignaseclant’s multi-domain improvements replicate over longer treatment horizons, it could validate skeletal muscle chloride channel inhibition as a platform across pre- and post-synaptic disorders, a thesis NMD is testing with upcoming myasthenia gravis and SMA data in 2026. In a capital market favoring de-risked, multi-indication assets, a first-in-class oral asset with convergent functional and PRO signals may draw partnership interest from neurology-focused acquirers, particularly as larger companies rebalance toward rare disease portfolios with clearer commercial pathways.
The next design choices will be decisive. Longer-duration Phase 2b/3 studies will likely need to prioritize composite functional measures and upper-limb endpoints, build in patient-reported outcomes acceptable to regulators and HTAs, and integrate digital or home-based assessments to capture real-world relevance. If those data show sustained, clinically meaningful benefit in a population with no alternatives, ignaseclant could set the benchmark for CMT treatment and shape payer expectations for future entrants. The open question is whether NMD can convert short-term, multi-endpoint signals into a registrational narrative that withstands regulatory scrutiny and delivers a value story compelling enough to define the first commercial standard in CMT.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
